Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CODX | US
-0.61
-18.83%
Healthcare
Diagnostics & Research
30/06/2024
12/03/2026
2.63
3.24
3.30
2.63
Co-Diagnostics Inc. a molecular diagnostics company develops manufactures and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19 influenza tuberculosis hepatitis B and C human papillomavirus malaria chikungunya dengue and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases liquid biopsy for cancer screening and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City Utah.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
533.4%1 month
372.8%3 months
279.2%6 months
446.7%-
16.00
0.56
0.04
0.03
0.52
0.12
-
-37.42M
83.93M
83.93M
-
-289.06
30.80
1.24K
-42.73
1.43
0.68
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.35
Range1M
2.35
Range3M
6.18
Rel. volume
0.85
Price X volume
345.05K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Anixa Biosciences Inc | ANIX | Diagnostics & Research | 2.86 | 92.03M | -2.72% | n/a | 1.09% |
| Sera Prognostics Inc. | SERA | Diagnostics & Research | 1.99 | 66.40M | 3.11% | n/a | 2.27% |
| ENDRA Life Sciences Inc | NDRA | Diagnostics & Research | 3.27 | 60.13M | -3.25% | n/a | 3.13% |
| Precipio Inc | PRPO | Diagnostics & Research | 28.775 | 42.65M | 2.88% | n/a | 9.66% |
| Cytosorbents Corporation | CTSO | Diagnostics & Research | 0.7257 | 39.50M | 0.10% | n/a | 159.92% |
| BioTelemetry Inc | BEAT | Diagnostics & Research | 1.47 | 39.05M | 8.09% | n/a | 0.00% |
| Neuronetics Inc | STIM | Diagnostics & Research | 1.27 | 38.48M | -1.55% | n/a | 323.03% |
| Biomerica Inc | BMRA | Diagnostics & Research | 1.97 | 33.14M | -2.48% | n/a | 13.22% |
| STAR EQUITY HOLDINGS INC | STRR | Diagnostics & Research | 9.915 | 31.94M | 1.17% | n/a | 26.85% |
| MYnd Analytics Inc | MYND | Diagnostics & Research | 0.49 | 22.37M | 15.89% | n/a | 117.50% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Reading International Inc | RDIB | Media - Diversified | 10.55 | 82.76M | -4.87% | n/a | 4054.78% |
| ILAG | ILAG | Building Products & Equipment | 2.25 | 40.64M | -14.12% | n/a | 5.48% |
| Reading International Inc | RDI | Media - Diversified | 1.1 | 31.05M | -2.65% | n/a | 4054.78% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.05 | 29.96M | -8.07% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.5643 | 10.90M | -3.54% | n/a | 58.43% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3953 | 3.76M | 18.11% | n/a | 19.98% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.36 | 3.47M | -2.02% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.4 | 1.32M | -0.41% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0092 | 848.37K | 29.58% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | 12.67 | Cheaper |
| Ent. to Revenue | 0.12 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 0.56 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 279.22 | 59.59 | Riskier |
| Debt to Equity | 0.04 | -14.36 | Expensive |
| Debt to Assets | 0.03 | 0.34 | Cheaper |
| Market Cap | 83.93M | 13.71B | Emerging |